These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1611118)

  • 1. Analysis of the effect of intravesical treatment with interferon-alpha 2b on the clinical evolution and on the in vivo function of T lymphocytes and natural killer cells in patients with superficial bladder tumors.
    Carballido J; Moltó LM; Olivier C; Manzano L; Alvarez-Mon M
    Anticancer Drugs; 1992 May; 3 Suppl 1():9-12. PubMed ID: 1611118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of intracavitary interferon-alpha-2b in the prophylactic treatment of patients with superficial bladder cancer.
    Moltó L; Alvarez-Mon M; Carballido J; Olivier C; Gimeno F; Manzano L
    Cancer; 1995 Jun; 75(11):2720-6. PubMed ID: 7743476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulatory effect of interferon-alpha 2b on natural killer cells and T lymphocytes from patients with transitional cell carcinoma of the bladder.
    Alvarez-Mon M; Moltó LM; Manzano L; Olivier C; Carballido JA
    Anticancer Drugs; 1992 May; 3 Suppl 1():5-8. PubMed ID: 1611117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder.
    Carballido JA; Moltó LM; Manzano L; Olivier C; Salmerón OJ; Alvarez de Mon M
    Cancer; 1993 Sep; 72(5):1743-8. PubMed ID: 8348503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma.
    Giannakopoulos S; Gekas A; Alivizatos G; Sofras F; Becopoulos T; Dimopoulos C
    Br J Urol; 1998 Dec; 82(6):829-34. PubMed ID: 9883220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of natural killer activity in patients with transitional cell carcinoma of the bladder.
    Carballido J; Alvarez-Mon M; Solovera OJ; Menéndez-Ondina L; Durántez A
    J Urol; 1990 Jan; 143(1):29-33. PubMed ID: 2294256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer (NK) cell assay within bladder mucosa of patients bearing transitional cell carcinoma (TCC) after interferon (IFN) therapy: an immunohistochemical and ultrastructural study.
    Natsis K; Toliou T; Stravoravdi P; Kirtsis P; Grekou A; Barich A; Konstantinidis E; Gigis P
    Int J Clin Pharmacol Res; 1997; 17(1):31-6. PubMed ID: 9403351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy.
    Agarwal A; Agrawal U; Verma S; Mohanty NK; Saxena S
    Immunopharmacol Immunotoxicol; 2010 Jun; 32(2):348-56. PubMed ID: 20105083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissecting the immunobiological effects of Bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon.
    Böhle A; Thanhäuser A; Ulmer AJ; Ernst M; Flad HD; Jocham D
    J Urol; 1993 Dec; 150(6):1932-7. PubMed ID: 8230540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Studies on stimulation of immunological responses resulting from intravesical BCG instillation in patients with bladder carcinomas].
    Tachibana M; Jitsukawa S; Deguchi N; Tazaki H
    Nihon Hinyokika Gakkai Zasshi; 1988 Oct; 79(10):1680-5. PubMed ID: 3251104
    [No Abstract]   [Full Text] [Related]  

  • 11. Prophylactic intracavitary treatment with interferon alpha increases interferon gamma production by peripheral blood mononuclear cells in patients with superficial transitional cell carcinoma of the bladder.
    Moltó L; Carballido J; Manzano L; Reyes E; Olivier C; Alvarez-Mon M
    Br J Cancer; 1997; 75(12):1849-53. PubMed ID: 9192993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Keyhole limpet hemocyanine can enhance the natural killer activity of patients with transitional cell carcinoma of the bladder.
    Moltó LM; Carballido J; Jurincic C; Lapeña P; Manzano L; Salmerón I; Klippel KF; Alvarez-Mon M
    Eur Urol; 1991; 19(1):74-8. PubMed ID: 2007423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Finnish Multicentre Study Group.
    Raitanen MP; Lukkarinen O
    Br J Urol; 1995 Dec; 76(6):697-701. PubMed ID: 8535711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical sequential combination of epirubicin and interferon alpha-2b in patients affected by superficial transitional cell carcinoma of the bladder. Results of a pilot study at Palermo University and proposal of a basic research.
    Serretta V; Corselli G; Pavone C; Pizzuto Antinoro SA; Pavone-Macaluso M
    Prog Clin Biol Res; 1991; 370():185-93. PubMed ID: 1924449
    [No Abstract]   [Full Text] [Related]  

  • 15. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
    Yutkin V; Pode D; Pikarsky E; Mandelboim O
    J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical immunotherapy for superficial bladder cancer.
    Said MT; Abomelha MS; Orkubi SA
    Saudi Med J; 2002 Dec; 23(12):1458-61. PubMed ID: 12518191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokines in superficial bladder cancer.
    da Silva FC
    Acta Urol Belg; 1996 May; 64(2):29-30. PubMed ID: 8701804
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
    Luciani LG; Neulander E; Murphy WM; Wajsman Z
    Urology; 2001 Sep; 58(3):376-9. PubMed ID: 11549484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T lymphocytes infiltrating the bladder wall of patients with carcinoma of urinary bladder are in vivo activated.
    Reyes E; Carballido J; Prieto A; Molto L; Manzano L; Alvarez-Mon M
    Eur Urol; 1997; 31(4):472-7. PubMed ID: 9187910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells.
    Chung JY; Lee ES; Lee WJ; Kim HH; Min KJ; Lee C
    J Korean Med Sci; 1993 Apr; 8(2):135-44. PubMed ID: 8397930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.